Mylan Matches Q4 Profit Forecasts and Beats on the Top Line

Mylan (MYL) released upbeat fourth quarter financial results after the closing bell on Monday. The pharmaceutical company reported adjusted earnings of $1.05 per share, on revenue of $2.08 billion for the quarter. The generic and specialty drug maker said it saw a boost in quarterly profit and revenue, driven primarily by strong demand in North America. Last week, the company said it completed its acquisition of Abbott Laboratories' (ABT) non-U.S. drug assets. Mylan will now be able to cut its tax bill by shifting its tax base to the Netherlands. TheStreet's Kurumi Fukushima reports in New York.